Agilent Technologies acquires Biocare Medical
The transaction brings together Agilent’s life sciences capabilities with Biocare’s specialized immunohistochemistry and molecular pathology solutions for cancer research and diagnostics.
Takeaways
- Biocare Medical is a global leader in immunohistochemistry and molecular pathology solutions.
- Agilent Technologies is acquiring Biocare Medical with backing from Excellere Partners and GHO Capital Partners LLP.
- The business serves cancer diagnostics and research.
Excellere Partners and GHO Capital have sold Biocare Medical, a global provider of immunohistochemistry and molecular pathology solutions, to Agilent Technologies.
Biocare specializes in automated instrumentation, reagents, and simultaneous multiplexing for IHC, ISH, and FISH applications, and it has built a reputation as a recognized specialist in these areas with strong commercial, regulatory, and R&D capabilities.
Under the two sponsors, Biocare posted double-digit annual revenue and profitability growth, expanded into molecular diagnostics, and strengthened its core IHC franchise.
The combination with Agilent aligns the companies’ strategies in life sciences and diagnostics, with the aim of unlocking broader market access and accelerating innovation for cancer diagnostics and research customers.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.